Collegium Pharma (COLL) Reports Q4 Loss of $1.02/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Collegium Reports Fourth Quarter Financial Results and Provides Corporate Update
March 9, 2017 4:01 PM ESTXtampza® ER prescribed by more than 2,400 physicians since commercial launchONSOLIS® patent issued that extends patent protection until 2027Well capitalized with $153.2 million in cash and cash equivalents
CANTON, Mass., March 09, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today reported its financial results for the fourth quarter of 2016 and provided a corporate update.Â
We have made significant progress on the commercial launch of Xtampza ER. Through mid-February, more than 2,400 physicians have prescribed Xtampza ER, including 800 first time prescribers in 2017 alone, stated Michael Heffernan, Collegiums... More
